You are here

Extending Genome-Phenome Analysis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42HG006974-02
Agency Tracking Number: R42HG006974
Amount: $1,459,019.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 172
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-16
Award End Date (Contract End Date): 2016-06-30
Small Business Information
Chestnut Hill, MA 02467-1823
United States
DUNS: 007086939
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (617) 566-6777
Business Contact
Phone: (617) 879-1670
Research Institution
9500 GILMAN DR, DEPT 0934
LA JOLLA, CA 92093-0934
United States

 Nonprofit College or University

DESCRIPTION provided by applicant The declining cost of whole exome sequencing WES is nearing the point at which the spread of WES into clinical practice will be limited largely by the cost of interpreting the results and comparing them to the patientandapos s clinical findings This project builds on our demonstrated capability to reduce this interpretation cost by pairing our diagnostic software in wide use for clinical diagnosis with automated genomic sequencing The clinical diagnostic software compares patients to andquot phenotypesandquot of findings in known diseases so the combination with genome analysis developed under an SBIR Phase grant is referred to as automated genome phenome analysis This award winning capability is valued because of its ability to analyze genomes in seconds and its hypothesis independent nature Here we propose to advance the genome phenome analysis as follows Aim is to generalize the analysis beyond the trio affected individual plus parents in order to support a wider variety of family structures These include nuclear families with more than one sibling families that extend beyond the nuclear family and unrelated affected individuals These capabilities will be useful in both clinical diagnosis and discovery of new connections between genes and diseases These capabilities will be added in a way that preserves the speed and hypothesis independent nature of the analysis Aim is to detect copy number variation CNV using exomes and analyze that genomic data in the clinical context Using WES for CNV analysis will lower the cost of diagnosis by reducing the need to order a microarray before exome analysis and will facilitate the automated analysis of DNA deletions and duplications in clinical care Aim is to improve the core analysis by taking into account which genes were well read but normal information that is important in excluding other diagnoses The analysis will also deal with situations of ambiguity over whether an affected individual is homozygous or heterozygous and do so in a way that only adds possibilities for diagnosis but doesnandapos t reduce possibilities considered by the original analysis Aim is to improve output by reporting on incidental findings and exporting information in ways that facilitate interactions with referring physicians and reporting of genome variants to public databases The overall goal is to improve accuracy and reduce the time and cost of analysis making WES more robust as a clinical tool as well as a tool for gene discovery Today interpretation costs exceed reimbursement rates and interviews with labs suggest that the major reason for high costs is the manual nature of the clinical correlation which we automate As the phenotype becomes known for a greater fraction of genetic abnormalities the applicability of our automated genome phenome analysis and the market for it will grow PUBLIC HEALTH RELEVANCE Advancing automated genome phenome analysis With the declining cost of whole exome and genome sequencing the main cost of such testing is becoming the cost of interpreting the huge amount of data that is generated This project combines the power of diagnostic software that examines all known diagnoses the andquot phenomeandquot with the power of whole exome sequencing to examine the genome and uses advanced capabilities such as compatibility with all family structures and the ability to take into account DNA deletions and duplications In automating the genome phenome analysis this project brings the power of genome analysis to clinical practice lowering costs while increasing accuracy

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government